436 related articles for article (PubMed ID: 28733853)
1. Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis.
Matsubara Y; Miyazaki O; Kosuga M; Okuyama T; Nosaka S
Pediatr Radiol; 2017 Nov; 47(12):1659-1669. PubMed ID: 28733853
[TBL] [Abstract][Full Text] [Related]
2. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.
Wang RY; Cambray-Forker EJ; Ohanian K; Karlin DS; Covault KK; Schwartz PH; Abdenur JE
Mol Genet Metab; 2009 Dec; 98(4):406-11. PubMed ID: 19748810
[TBL] [Abstract][Full Text] [Related]
3. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
[TBL] [Abstract][Full Text] [Related]
4. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
5. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
Miebach E
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S100-6. PubMed ID: 20040319
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of enzyme replacement therapy on cardiac findings in patients with mucopolysaccharidosis.
Bilginer Gurbuz B; Aypar E; Coskun T; Alehan D; Dursun A; Tokatli A; Sivri HS
J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1049-1053. PubMed ID: 31469658
[TBL] [Abstract][Full Text] [Related]
7. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
8. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
9. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI.
Brands MM; Frohn-Mulder IM; Hagemans ML; Hop WC; Oussoren E; Helbing WA; van der Ploeg AT
J Inherit Metab Dis; 2013 Mar; 36(2):227-34. PubMed ID: 22278137
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy: efficacy and limitations.
Concolino D; Deodato F; Parini R
Ital J Pediatr; 2018 Nov; 44(Suppl 2):120. PubMed ID: 30442189
[TBL] [Abstract][Full Text] [Related]
11. Functional capacity evaluation of patients with mucopolysaccharidosis.
Guarany NR; Schwartz IV; Guarany FC; Giugliani R
J Pediatr Rehabil Med; 2012; 5(1):37-46. PubMed ID: 22543891
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations.
Parini R; Deodato F
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340185
[TBL] [Abstract][Full Text] [Related]
14. Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study.
Sestito S; Rinninella G; Rampazzo A; D'Avanzo F; Zampini L; Santoro L; Gabrielli O; Fiumara A; Barone R; Volpi N; Scarpa M; Tomanin R; Concolino D
Orphanet J Rare Dis; 2022 Jun; 17(1):251. PubMed ID: 35768874
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
[TBL] [Abstract][Full Text] [Related]
17. Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA.
Lin HY; Chen MR; Lin SM; Hung CL; Niu DM; Chuang CK; Lin SP
Orphanet J Rare Dis; 2018 Aug; 13(1):148. PubMed ID: 30157891
[TBL] [Abstract][Full Text] [Related]
18. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
Tylki-Szymańska A; Almássy Z; Christophidou-Anastasiadou V; Avdjieva-Tzavella D; Barisic I; Cerkauskiene R; Cuturilo G; Djiordjevic M; Gucev Z; Hlavata A; Kieć-Wilk B; Magner M; Pecin I; Plaiasu V; Samardzic M; Zafeiriou D; Zaganas I; Lampe C
Orphanet J Rare Dis; 2022 Mar; 17(1):136. PubMed ID: 35331284
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
[TBL] [Abstract][Full Text] [Related]
20. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
